首頁 > 市場調查報告書 > 製藥

消化器

市場調查報告書

商品編碼

2054958

潰瘍性大腸炎治療市場：依分子類型、藥物類別、疾病類型、疾病嚴重程度、給藥途徑、年齡層、性別、通路、最終用戶和地區分類

Ulcerative Colitis Drug Market, By Molecule Type, By Drug Class, By Disease Type, By Disease Severity, By Route of Administration, By Age Group, By Gender, By Distribution Channel, By End User, By Geography

出版日期: 2026年03月17日 | 出版商:

Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

潰瘍性大腸炎治療市場預計在 2026 年達到 101.6 億美元，預計到 2033 年將達到 159.9 億美元。預計從 2026 年到 2033 年，該市場將以 6.7% 的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	101.6億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	6.70%	2033年市場規模預測：	159.9億美元

全球潰瘍性大腸炎治療市場是製藥業的重要組成部分，它針對的是影響全球數百萬名患者最常見的發炎性腸道疾病之一。潰瘍性大腸炎是一種主要涉及結腸和直腸的慢性發炎性疾病，其特徵是病情反覆緩解和復發，嚴重影響患者的生活品質。該市場涵蓋多種治療方法，包括氨基水楊酸類藥物、皮質類固醇、免疫抑制劑、生物製藥以及旨在控制發炎、誘導緩解和阻止疾病進展的新型標靶治療。

潰瘍性大腸炎，尤其是在已開發國家，加上人們對發炎性腸道疾病的認知不斷提高，正推動研發領域的巨額投資。製藥公司不斷創新，致力於開發更有效、安全性更高、給藥途徑更便利的標靶治療。市場正經歷著向個人化醫療的模式轉移，基於生物標記的治療策略日益受到重視。此外，生物相似藥的廣泛應用和新型藥物遞送系統的出現，正在重塑競爭格局，使全球患者更容易獲得治療，且治療費用也更加親民。

市場動態

全球潰瘍性大腸炎治療市場主要受以下幾個關鍵因素驅動，這些因素共同推動了其強勁的成長動能。潰瘍性大腸炎在全球範圍內的盛行率不斷上升，尤其是在北美和歐洲，這是其成長要素。環境因素、生活方式的改變以及遺傳易感性都導致了發病率的上升。藥物研發，特別是生物製藥和標靶治療的顯著進步，正在革新治療效果，並隨著醫療專業人員採用更有效的治療方案而推動市場擴張。患者和醫療專業人員對發炎性腸道疾病的認知不斷提高，以及診斷能力的提升，促進了疾病的早期發現和治療，從而擴大了患者群體。

政府支持罕見疾病研究的舉措以及已開發市場優惠的報銷政策正在進一步加速市場成長。然而，也存在諸多限制因素。尤其是在醫療預算有限的新興國家，生物製藥療法的高成本限制了病患的用藥。嚴格的藥品核准監管要求、漫長的臨床試驗流程以及針對不同患者群體開發治療方法的複雜性，都給市場相關人員帶來了巨大挑戰。專利到期以及生物相似藥的湧入可能會造成價格壓力，並影響收入成長。儘管面臨這些挑戰，在擁有龐大患者群體和正在發展中的醫療基礎設施的新興市場，仍蘊藏著巨大的機會。個人化醫療方法、新型藥物遞送系統和聯合治療的開發具有巨大的成長潛力。

本次調查的主要特點

本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
本研究根據以下參數對全球潰瘍性大腸炎治療市場的主要參與者進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份「全球潰瘍性大腸炎治療市場報告」旨在為該行業的各種相關人員提供服務，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
透過分析全球潰瘍性大腸炎治療市場中使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第14章競爭格局

AbbVie Inc
Johnson & Johnson（Janssen Biotech）
Pfizer Inc
Bristol Myers Squibb Company
Eli Lilly and Company
Takeda Pharmaceutical Company Limited
Amgen Inc
Novartis AG
Merck & Co Inc
Gilead Sciences Inc
Boehringer Ingelheim International GmbH
Hoffmann-La Roche Ltd
Biogen Inc
Celltrion Healthcare Co Ltd
Eisai Co Ltd

第15章分析師建議

機會分析
分析師意見
Coherent Opportunity Map

第16章參考文獻與調查方法

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI8592

Ulcerative Colitis Drug Market is estimated to be valued at USD 10.16 Bn in 2026 and is expected to reach USD 15.99 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.7% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 10.16 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	6.70%	2033 Value Projection:	USD 15.99 Bn

The global ulcerative colitis drug market represents a critical segment within the pharmaceutical industry, addressing one of the most prevalent inflammatory bowel diseases affecting millions of patients worldwide. Ulcerative colitis is a chronic inflammatory condition that primarily affects the colon and rectum, characterized by periods of remission and flare-ups that significantly impact patients' quality of life. The market encompasses a diverse range of therapeutic interventions including aminosalicylates, corticosteroids, immunosuppressants, biologics, and emerging targeted therapies designed to manage inflammation, induce remission, and prevent disease progression.

The increasing prevalence of ulcerative colitis, particularly in developed regions, coupled with rising awareness about inflammatory bowel diseases, has driven substantial investment in research and development activities. Pharmaceutical companies are continuously innovating to develop more effective, targeted therapies with improved safety profiles and convenient administration routes. The market is witnessing a paradigm shift toward personalized medicine approaches, with biomarker-driven treatment strategies gaining prominence. Additionally, the growing adoption of biosimilars and the emergence of novel drug delivery systems are reshaping the competitive landscape, making treatments more accessible and affordable for patients globally.

Market Dynamics

the global ulcerative colitis drug market is primarily driven by several key factors that collectively contribute to its robust growth trajectory. The increasing global prevalence of ulcerative colitis, particularly in North America and Europe, serves as the fundamental growth driver, with environmental factors, lifestyle changes, and genetic predisposition contributing to rising incidence rates. Significant advancements in drug development, particularly in biologics and targeted therapies, have revolutionized treatment outcomes, driving market expansion as healthcare providers adopt more effective therapeutic options. The growing awareness among patients and healthcare professionals about inflammatory bowel diseases, coupled with improved diagnostic capabilities, has led to earlier detection and treatment initiation, thereby expanding the patient pool.

Government initiatives supporting rare disease research and favorable reimbursement policies in developed markets further accelerate market growth. However, the market faces notable restraints including the high cost of advanced biologic therapies, which limits patient access, particularly in emerging economies with constrained healthcare budgets. Stringent regulatory requirements for drug approval, lengthy clinical trial processes, and the complexity of developing treatments for heterogeneous patient populations pose significant challenges for market players. Patent expiries of blockbuster drugs and the subsequent entry of biosimilars create pricing pressures, potentially impacting revenue growth. Despite these challenges, substantial opportunities exist in the form of untapped emerging markets with large patient populations and improving healthcare infrastructure. The development of personalized medicine approaches, novel drug delivery systems, and combination therapies presents significant growth potential.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global ulcerative colitis drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include AbbVie Inc, Johnson and Johnson (Janssen Biotech), Pfizer Inc, Bristol Myers Squibb Company, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc, Novartis AG, Merck and Co Inc, Gilead Sciences Inc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, Biogen Inc, Celltrion Healthcare Co Ltd, and Eisai Co Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global ulcerative colitis drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ulcerative colitis drug market

Market Segmentation

Molecule Type Insights (Revenue, USD Bn, 2021 - 2033)
Biologics
Small Molecules
Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
Aminosalicylates
- Mesalamine (Asacol HD, Lialda)
- Olsalazin
Corticosteroids
- Budesonide (Uceris)
- Prednisone
Anti-TNF Biologics
- Infliximab (Remicade)
- Adalimumab (Humira)
Integrin Receptor Antagonists
- Vedolizumab (Entyvio)
Janus Kinase (JAK) Inhibitors
- Tofacitinib (Xeljanz)
- Upadacitinib (Rinvoq)
Interleukin (IL)-12/23 Inhibitors
- Ustekinumab (Stelara)
- Risankizumab (Skyrizi)
Sphingosine 1-Phosphate (S1P) Receptor Modulators
- Ozanimod (Zeposia)
- Etrasimod (Velsipity)
Immunosuppressants
- Azathioprine
- 6-Mercaptopurine
Others
Disease Type Insights (Revenue, USD Bn, 2021 - 2033)
Ulcerative Proctitis
Left-Sided Colitis
Pancolitis
Fulminant Colitis
Disease Severity Insights (Revenue, USD Bn, 2021 - 2033)
Mild Ulcerative Colitis
Moderate Ulcerative Colitis
Severe Ulcerative Colitis
Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
Oral
Parenteral
Rectal
Age Group Insights (Revenue, USD Bn, 2021 - 2033)
Adults
Pediatrics
Geriatric
Gender Insights (Revenue, USD Bn, 2021 - 2033)
Male
Female
Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
End User Insights (Revenue, USD Bn, 2021 - 2033)
Hospitals and Clinics
Infusion Centers
Specialty Gastroenterology Clinics
Ambulatory Surgical Centers (ASCs)
Research and Diagnostic Laboratories
Home Healthcare Settings
Regional Insights (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
AbbVie Inc
Johnson & Johnson (Janssen Biotech)
Pfizer Inc
Bristol Myers Squibb Company
Eli Lilly and Company
Takeda Pharmaceutical Company Limited
Amgen Inc
Novartis AG
Merck & Co Inc
Gilead Sciences Inc
Boehringer Ingelheim International GmbH
Hoffmann-La Roche Ltd
Biogen Inc
Celltrion Healthcare Co Ltd
Eisai Co Ltd

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Ulcerative Colitis Drug Market, By Molecule Type
- Global Ulcerative Colitis Drug Market, By Drug Class
- Global Ulcerative Colitis Drug Market, By Disease Type
- Global Ulcerative Colitis Drug Market, By Disease Severity
- Global Ulcerative Colitis Drug Market, By Route of Administration
- Global Ulcerative Colitis Drug Market, By Age Group
- Global Ulcerative Colitis Drug Market, By Gender
- Global Ulcerative Colitis Drug Market, By Distribution Channel
- Global Ulcerative Colitis Drug Market, By End User
- Global Ulcerative Colitis Drug Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Ulcerative Colitis Drug Market, By Molecule Type, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Biologics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Small Molecules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Global Ulcerative Colitis Drug Market, By Drug Class, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Aminosalicylates
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  - Mesalamine (Asacol HD, Lialda)
  - Olsalazin
Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  - Budesonide (Uceris)
  - Prednisone
Anti-TNF Biologics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  - Infliximab (Remicade)
  - Adalimumab (Humira)
Integrin Receptor Antagonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  - Vedolizumab (Entyvio)
Janus Kinase (JAK) Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  - Tofacitinib (Xeljanz)
  - Upadacitinib (Rinvoq)
Interleukin (IL)-12/23 Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  - Ustekinumab (Stelara)
  - Risankizumab (Skyrizi)
Sphingosine 1-Phosphate (S1P) Receptor Modulators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  - Ozanimod (Zeposia)
  - Etrasimod (Velsipity)
Immunosuppressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  - Azathioprine
  - 6-Mercaptopurine
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Global Ulcerative Colitis Drug Market, By Disease Type, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Ulcerative Proctitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Left-Sided Colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Pancolitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Fulminant Colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Global Ulcerative Colitis Drug Market, By Disease Severity, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Mild Ulcerative Colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Moderate Ulcerative Colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Severe Ulcerative Colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

8. Global Ulcerative Colitis Drug Market, By Route of Administration, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Rectal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

9. Global Ulcerative Colitis Drug Market, By Age Group, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Pediatrics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

10. Global Ulcerative Colitis Drug Market, By Gender, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

11. Global Ulcerative Colitis Drug Market, By Distribution Channel, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

12. Global Ulcerative Colitis Drug Market, By End User, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Infusion Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Specialty Gastroenterology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Ambulatory Surgical Centers (ASCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Research and Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Home Healthcare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

13. Global Ulcerative Colitis Drug Market, By Region, 2021 - 2033, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Molecule Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Severity, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Molecule Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Severity, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Molecule Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Severity, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Molecule Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Severity, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Molecule Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Severity, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Molecule Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Severity, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

14. Competitive landscape

AbbVie Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson (Janssen Biotech)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Gilead Sciences Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Biogen Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Celltrion Healthcare Co Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eisai Co Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies